Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 6/20 | 0.39 |
| ▸ | JUN | P05412 | 5/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | TTK | P33981 | 1/20 | 0.38 |
| ▸ | CCNC | P24863 | 2/20 | 0.37 |
| ▸ | CDK8 | P49336 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 4/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.37 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.36 |
| ▸ | WNT1 | P04628 | 1/20 | 0.36 |
| ▸ | STAT6 | P42226 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13336219 | 0.92 | GSK3B (0.42) | SYKCDK1TTKGSK3BDYRK1A | |
| SCHEMBL13336250 | 0.91 | SYK (0.42) | SYKAURKAAURKBMAPK10JUN | |
| SCHEMBL13336222 | 0.89 | TTK (0.45) | SYKMAPK10JUNKDRTTK | |
| SCHEMBL1570539 | 0.85 | SYK (0.45) | SYKMAPK10JUNMAPK8MAPK9 | |
| SCHEMBL13336218 | 0.82 | TYRO3 (0.39) | CDK1KDRTTKGSK3BDYRK1A | |
| SCHEMBL13574022 | 0.80 | GSK3B (0.44) | SYKCDK1TTKGSK3BDYRK1A | |
| SCHEMBL13336128 | 0.79 | GSK3B (0.43) | SYKCDK1TTKGSK3BDYRK1A | |
| SCHEMBL13574026 | 0.79 | GSK3B (0.43) | SYKCDK1TTKGSK3BDYRK1A | |
| SCHEMBL13336280 | 0.79 | CDK2 (0.39) | CDK1TTK | |
| SCHEMBL13336089 | 0.78 | SYK (0.53) | SYKAURKAAURKBMAPK10JUN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| WO-2009153313-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | SYK 4070/4885AURKA 845/4885AURKB 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.